Gene Therapies

In the centuries-long journey of medical science, one of the greatest peaks reached by humanity has undoubtedly been solving the genetic puzzle. Hereditary eye diseases, which until recently were defined as "hopeless," "progressive," and "resulting in certain blindness," are now transforming into treatable medical conditions thanks to Gene Therapies—the cellular and molecular revolution of the 21st century. As Ophthalmology Specialist Ayşe Öner and her leading clinical team, who command the international literature on genetic retinal diseases, we blend these high-tech treatments that turn science fiction into reality with Turkey's superior healthcare infrastructure. With our global vision in health tourism, we promise our patients coming to Turkey from the farthest corners of the world more than just a medical intervention; we offer genetic counseling, zero waiting times, VIP accommodation, and a seamless health travel experience in their native language. Do not submit to darkness as a fate written in your genes; prepare to be reborn through the light of science.

What is Gene Therapy? Getting to the Root of the Disease

In the nucleus of every cell in the human body lies a manual that determines how that cell works, which proteins it will produce, and how it will survive: the DNA (genetic code). The light-sensitive cells in the retina, which initiate the process of vision, also operate according to these genetic instructions. However, in some cases, a "typo" (mutation) occurs in the genes inherited from parents. Due to this faulty coding, vital proteins required for the retina to function healthily cannot be produced. Consequently, cells degenerate, lose function, and progressive, severe vision loss emerges during childhood, youth, or middle age.

Gene therapy is a revolutionary medical approach that aims to solve the problem not through symptoms (such as merely lowering eye pressure), but directly at the source—the DNA level. The fundamental logic is to replace the faulty or non-functioning gene in the patient's cells with a healthy, normally functioning genetic copy (DNA) produced in a laboratory.

How is Gene Therapy Applied to the Eye? (Viral Vector Technology)

It is impossible for a healthy gene to enter the nucleus of microscopic nerve cells inside the eye on its own. To carry this new and healthy genetic copy into the cell, specialized carriers called "vectors" are needed. The medical world uses viruses—nature's masters at transferring genetic material into human cells—for this transport process.

These are not disease-causing viruses. In a laboratory, Adeno-Associated Viruses (AAV) are used, from which harmful genetic material has been removed, leaving only a "cargo vehicle."

The Application Process:

1. The healthy gene copy is loaded into these harmless viruses.
2. The procedure is performed in fully equipped, JCI-accredited smart operating rooms using microsurgical (Vitrectomy) methods.
3. Using specialized cannulas thinner than a strand of hair, the surgeon performs a precise injection under the retina (subretinal space), delivering millions of "cargo viruses" directly to the target cells.
4. The viruses transfer the healthy genes to the patient's retinal cells. The cells begin to read this new manual, produce the missing proteins, and the progression of the disease halts immediately, often resulting in striking improvements in vision.

Which Eye Diseases are Treated with Gene Therapy?

The spectrum of gene therapies in ophthalmology is expanding rapidly. Today, in addition to treatments approved by the FDA and EMA, there are dozens of promising Phase-2 and Phase-3 studies:

1. RPE65 Gene Mutation (Luxturna)

This is the greatest success story in modern medicine. It is the treatment for mutations in the RPE65 gene, which causes Leber Congenital Amaurosis (LCA) and some forms of early-onset Retinitis Pigmentosa. With Luxturna, the first approved gene therapy in the world, patients can step from darkness into light very quickly, miraculously increasing their night vision and independent mobility.

2. Other Hereditary Retinal Diseases (In Clinical Trial Stages):

1. Stargardt Disease (ABCA4 Gene): Nano-carriers and gene-editing technologies are being tested for this large gene.
2. Choroideremia (CHM Gene): AAV-vectored gene therapy for this disease, which causes progressive visual field loss and night blindness, is in Phase-3.
3. X-Linked Retinitis Pigmentosa (RPGR Gene): Promising trials continue for this genetic type that progresses severely in males.
4. Achromatopsia: Therapies for the CNGA3 and CNGB3 genes aim to correct extreme light sensitivity and visual acuity.

Future Technology: CRISPR-Cas9 (Gene Editing)

While classic gene therapy adds a "new gene" to the cell, CRISPR-Cas9 (Gene Scissors) technology acts differently. Instead of sending a new gene, it uses microscopic molecular scissors to cut out the "faulty letter" in the patient's own DNA and paste the correct one. CRISPR treatments applied directly to the human eye for LCA Type 10 (CEP290 gene) herald a new era in ophthalmology.

The Vital Importance of Genetic Mapping

To discuss gene therapy, simply knowing the name of the disease (e.g., Night Blindness) is not enough. The "specific gene" causing the disease must be identified in a laboratory. Our clinic provides a comprehensive process:

1. Next-Generation Sequencing (NGS): DNA from blood or saliva is screened for hundreds of retinal genes simultaneously.
2. ERG and OCT: High-tech devices map the viability of retinal cells. We measure with micron-level precision whether enough "living cells" remain to accept the gene therapy.

Why Turkey and Dr. Ayşe Öner for Health Tourism?

Genetic eye diseases require a specific "Genetic-Retina" expertise. In many Western health systems, patients lose years fighting bureaucratic hurdles for genetic testing or specialist appointments. In genetic diseases, every month lost means irreversible cell death.

Our clinic transforms this complex process into a VIP experience:

1. Time-Sensitive Service: Upon arrival in Turkey, tests like ERG and OCT are completed with zero wait time, and genetic samples are shipped to world-class accredited labs the same day.
2. Scientific and Transparent Counseling: Once results are ready, Dr. Ayşe Öner explains your mutation type and global treatment options in your native language.
3. End-to-End Comfort: We manage VIP airport greetings, luxury accommodation, and all transfers, allowing you to focus entirely on your healing.
4. Global Genetic Watchlist: If no approved treatment exists for your specific mutation yet, you are recorded in our Global Genetic Waiting List. You will be among the first to be informed the moment an FDA/EMA approval emerges for your gene.

Contact our international patient coordination unit immediately to meet the highest level of medical science and step toward a brighter life with the assurance of Turkey's unique health tourism. The medicine of the future is here today for your eyes.